Molecular epidemiology of serotype 19A Streptococcus pneumoniae among invasive isolates from Alaska, 1986&#x2013;2010 by Karen Rudolph et al.
Molecular epidemiology of serotype 19A
Streptococcus pneumoniae among
invasive isolates from Alaska,
19862010
Karen Rudolph*, M.G. Bruce, L. Bulkow, T. Zulz, A. Reasonover,
M. Harker-Jones, D. Hurlburt and T.W. Hennessy
Arctic Investigations Program, Division of Preparedness and Emerging Infections, National Center for
Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention (CDC)
Background. After the introduction of the 7-valent pneumococcal conjugate vaccine (PCV7) in Alaska, the
incidence of invasive pneumococcal disease (IPD) due to non-vaccine serotypes, particularly serotype 19A,
increased. The aim of this study was to describe the molecular epidemiology of IPD due to serotype 19A in
Alaska.
Methods. IPD data were collected from 1986 to 2010 through population-based laboratory surveillance.
Isolates were serotyped by the Quellung reaction and MICs determined by broth microdilution. Genotypes
were assessed by multilocus sequence typing.
Results. Among 3,294 cases of laboratory-confirmed IPD, 2,926 (89%) isolateswere available for serotyping, of
which 233 (8%) were serotype 19A. Across all ages, the proportion of IPD caused by serotype 19A increased
from 3.5% (63/1823) pre-PCV7 (19862000) to 15.4% (170/1103) post-PCV7 (20012010) (pB0.001); among
children B5 years of age, the proportion increased from 5.0% (39/776) to 33.0% (76/230) (pB0.001). The
annual incidence rate of IPD due to serotype 19A (all ages) increased from 0.73 cases pre-PCV7 to 2.56 cases/
100,000 persons post-PCV7 (pB0.001); rates among children B5 years of age increased from 4.84 cases to
14.1 cases/100,000 persons (pB0.001). Among all IPD isolates with reduced susceptibility to penicillin, 17.8%
(32/180) were serotype 19A pre-PCV7 and 64% (121/189) were serotype 19A post-PCV7 (pB0.001). Eighteen
different sequence types (STs) were identified; ST199 or single locus variants of ST199 (n150) and ST172
(n59) accounted for the majorityof isolates. Multidrug-resistant isolateswere clustered in ST199 and ST320.
Conclusion. While PCV13 should significantly reduce the burden of disease due to 19A, these data highlight
the need to continue surveillance for IPD to monitor the effects of vaccination on the expansion and
emergence of non-PCV strains.
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S
treptococcus pneumoniae is a major cause of
invasive diseases, such as bacteremia, septicemia
and meningitis, and less severe conditions such as
middle-ear infections, sinusitis and recurrent bronchitis.
Worldwide, pneumococci cause over 1 million deaths
annually, mainly among children B5 years of age, mostly
in developing countries. In addition to being a major
cause of morbidity and mortality worldwide, pneumo-
cocci are also becoming more resistant to commonly used
antibiotics. One of the strategies used to reduce both the
incidence of invasive disease and the spread of antibiotic-
resistant isolates is administration of vaccines directed
against the polysaccharide capsule. In children B2 years
of age, where the greatest burden of disease exists, recent
efforts to develop effective pneumococcal vaccines have
been concentrated on conjugate vaccines in which the
capsular polysaccharides are covalently coupled to carrier
proteins. The first such conjugate vaccine (PCV7), which
was introduced into the universal immunization pro-
gram in the United States in 2000, contained the 7 most
common pneumococcal serotypes (4, 6B, 9V, 14, 18C,
19F and 23F) causing invasive disease in infants and
young children prior to its introduction in 2000. After the
introduction of the 7-valent pneumococcal conjugate
vaccine (PCV7), the incidence of invasive pneumococcal
disease (IPD) caused by vaccine serotypes decreased
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However, rates of IPD caused by non-vaccine serotypes,
particularly serotype 19A, increased (410).
Prior to the introduction of PCV7 into the routine
vaccination schedule in Alaska, rates of invasive pneu-
mococcal disease among Alaska Native persons were
among the highest reported, particularly among Native
children B2 years of age where rateswere 3.5 times higher
than observed in non-Native children of the same age
(11,12). Following the introduction of PCV7 in Alaska in
2001, the rate of vaccine-type invasive disease among
Alaska Native children B2 years of age declined by 92%
with a similar decline in rates among non-Native children
of the same age (9). In addition, invasive disease due
to antibiotic-resistant serotypes decreased, however, our
statewide surveillance data from 2001 to 2010 revealed an
increase in IPD due to serotype 19A among all age groups.
Here we describe the antimicrobial susceptibilities and
genetic backgrounds of serotype 19A IPD isolates in
the 15 years before the introduction of PCV7 and in the
10 years following vaccine introduction.
Material and methods
Population studied
Alaska’s population of 710,000 (2010 US census) includes
142,000 (20%) Alaska Native (AN) and American Indian
peoples, with 7,100 younger than 2 years of age. Sixty-five
percent of Alaska Native peoples live in rural commu-
nities, many of which are isolated villages with popula-
tions ranging from 50 to 1000 persons. Health care for
the AN population is provided through a statewide
tribally-operated health delivery system which includes
community health practitioners at the village level, pri-
mary care providers in regional hub communities and a
referral hospital in Anchorage.
Invasive disease surveillance (19862010)
The Arctic Investigations Program (AIP) established
a population-based statewide surveillance system to
monitor invasive pneumococcal disease (IPD) in 1986.
Isolates of S. pneumoniae are received at the AIP labo-
ratory, Anchorage, AK, from 23 regional hospital labo-
ratories processing sterile site specimens (blood and
cerebrospinal, pleural, peritoneal or joint fluid) in the
state. Pneumococci were confirmed by colony morphol-
ogy, susceptibility to optochin (Difco, Detroit) and bile
solubility. All isolates were serotyped by slide agglutina-
tion and confirmed by the Quellung reaction using
group- and type-specific antisera (Staten Serum Institute,
Copenhagen, Denmark).
Antimicrobial susceptibility testing
Susceptibility testing was performed by use of the broth
microdilution method as described by the Clinical and
Laboratory Standards Institute (CLSI) for penicillin,
erythromycin, trimethoprim-sulfamethoxazole (TS), tet-
racycline, chloramphenicol, ceftriaxone, cefotaxime, van-
comycin and rifampin (13). The MIC was determined to
be the lowest concentration of antibiotic that inhibited
growth. The 2007 interpretive CLSI guidelines were used
to define non-susceptibility and included isolates that
were either intermediately resistant or fully resistant to
a particular antibiotic (13). Multidrug-resistant isolates
were defined as having intermediate or full resistance to
three or more different classes of antibiotics.
Macrolide resistance genotypes
Erythromycin-resistant serotype 19A isolates were ana-
lysed for the presence of ermB and mef genes using a
duplex PCR assay. Bacterial cells were suspended in 0.1
ml of nuclease free H2O, heated at 1008C for 10 min,
centrifuged at 13,000 rpm for 5 min and stored at 308C
until used. Erythromycin-resistance genes ermB and mef
were screened using primer sets designed by Sutcliff et al.
and Tait-Kamradt et al., respectively (14,15). PCR was
performed in a total volume of 25 ml consisting of 12.5 ml
AmpliTaq Gold† (Applied Biosystems, Foster City, CA),
3.0 ml of DNA lysate, 0.5 mM of each ermB primer and
2.0 mM of each mef primer. Amplifications were per-
formed in a Perkin-Elmer GeneAmp PCR system 9700
(Applied Biosystems) under the following conditions:
948C for 3 min followed by 30 cycles of 948C for 45 s,
538C for 30 s and 728C for 2 min with a final extension
at 728C for 5 min. Negative controls contained the
PCR mixture without the DNA template; positive con-
trols contained S. pneumoniae DNA from erythromycin-
resistant strains known to carry either mef or ermB.
Amplification products were run through 3% Ready-
Agarose
TM gels (Bio-Rad, Hercules, CA) in 1X TAE
(Invitrogen, Carlsbad, CA) at 100 V for 60 min. PCR
product size for the ermB and mef genes are 639 bp
and 940 bp, respectively. The PCR products of the mef
gene were digested with DraI (Promega, Madison, WI)
in order to discriminate between the mefA and mefE
subclasses (16).
MLST analysis
Multilocus sequence typing (MLST) was performed
as previously described (17), with modifications (7) on
all viable serotype 19A isolates recovered from 1986
2010. The sequence types (ST) were determined by com-
paring the sequences with alleles downloaded from the
pneumococcal MLST database (http://spneumoniae.mlst.
net). Clonal complexes were assigned using the eBURST
algorithm with the software available at the MLST
website (http://www.mlst.net).
Statistical analysis
Disease rates by period were compared using mid-P
exact significance. Proportions of isolates were compared
using Chi-square or Fisher’s exact test as appropriate.
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values are two-sided and a p-value of B0.05 is con-
sidered statistically significant.
Results
Bacterial isolates and incidence
From 1986 to 2010, 3294 cases of culture-confirmed
invasive pneumococcal disease (IPD) were reported to
AIP. Of these cases, 2926 (89%) isolates were available for
serotyping of which 233 (8%) were serotype 19A. Rates
of IPD due to serotype 19A increased significantly
(pB0.001) after the introduction of PCV7 in Alaska.
The annual incidence rate of IPD due to serotype 19A
among all ages increased from 0.73 cases per 100,000
persons pre-PCV7 (19862000) to 2.56 cases per 100,000
persons post-PCV7 (20012010) (pB0.001) (Table I).
The annual incidence rate of IPD due to serotype 19A
among children B5 years of age increased from 4.84
cases per 100,000 persons pre-PCV7 to 14.1 cases per
100,000 persons post-PCV7 (pB0.001). The proportion
of IPD caused by serotype 19A among all age groups
increased from 3% (63/1823) pre-PCV7 to 15% (170/1103)
post-PCV7 (pB0.0001). Among children B5 years of
age, the proportion of IPD caused by serotype 19A
increased from 5% (39/776) pre-PCV7 to 33% (76/230)
post-PCV7 (pB0.0001). Common clinical presentations
among serotype 19A IPD cases included pneumonia
with bacteremia (156, 67%), bacteremia (57, 24%) and
meningitis (12, 5%).
MLST
Of the 233 serotype 19A isolates, 231 were available for
molecular typing. MLST analysis revealed 18 sequence
types (ST) (Fig. 1). Six STs were unique to the 19862000
isolates and nine STs were unique to the 20012010
isolates. Four STs (3976, 4092, 4151, 6994) were new to
the MLST database at the time of this analysis. Of the
nine STs found among the serotype 19A isolates recov-
ered during the pre-PCV7 period (19862000), three STs
(199, 667, 172) accounted for 90% (55/61) of the isolates.
Of the 12 STs found among the serotype 19A isolates
recovered during the post-PCV7 period (20012010),
only three STs (199, 667, 172) were found in the pre-
PCV7 period. These three STs accounted for 76% (130/
170) of the serotype 19A isolates recovered in this time
period. Among the remaining 40 serotype 19A isolates
recovered during the post-PCV7 period, three STs (320,
1756, 3976) accounted for 85% (33/40) of the isolates.
The most frequent STacross the entire time period was
ST199 and, along with closely related single- and double-
locus variants form clonal complex (CC) 199, accounting
for the majority (65%, 150/231) of the isolates (Fig. 1).
However, the proportion of CC199 isolates decreased
from 90% (55/61) in 19862000 to 56% (95/170) in 2001
2010, which was statistically significant (pB0.001) (Table
II). The second most frequent ST was ST172 which
accounted for 26% (59/231) of the isolates. ST172 isolates
were first seen in 2000 and increased significantly over
time. By the later part of the post-PCV7 era (20062010),
ST172 isolates accounted for 33% of serotype 19A
isolates. During this same time period, we observed the
introduction of CC320 (ST320 and ST1451) isolates into
this population. These isolates accounted for 13% (15/
118) of the serotype 19A isolates in this time period.
A total of 40% of CC320 isolates were recovered from
children B2 years of age and, while this proportion was
higher than for ST172 and CC199 isolates, it was not
statistically significant. Likewise, we did not observe
statistically significant differences with regards to clinical
syndromes, sex, or case fatality when comparing IPD
caused by CC320 isolates with IPD caused by the other
serotype 19A genotypes.
Antimicrobial susceptibility
Among all IPD isolates with reduced susceptibility to
penicillin, 18% (32/180) were serotype 19A pre-PCV7 and
64% (121/189) were serotype 19A post-PCV7 (pB0.001).
The proportion of serotype 19A isolates that were
non-susceptible to penicillin (MIC]0.12 mg/ml), erythro-
mycin, and TS increased significantly in the post-PCV7
era (Table III). While not statistically significant, we also
observed an increase in the proportion of serotype 19A
isolates with reduced susceptibility to cefotaxime and
ceftriaxone. Among all IPD isolates that were multidrug
Table I. Annual incidence of serotype 19A and non-serotype 19A IPD in Alaska, pre-PCV7 (19862000) and post-PCV7 (20012010)
Number of cases (rate per 100,000 population)
19862000 20012010 p-Value for change in rate
Age (yrs) 19A Non-19A serotypes 19A Non-19A serotypes 19A Non-19A serotypes
B5 39 (4.84) 737 (91.5) 76 (14.1) 154 (28.5) B0.001 B0.001
5 24 (0.31) 1023 (13.1) 94 (1.54) 779 (12.7) B0.001 0.611
Total 63 (0.73) 1760 (20.4) 170 (2.56) 933 (14.0) B0.001 B0.001
A p-value of B0.05 is considered statistically significant.
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49% (37/76) were serotype 19A post-PCV7. Among the
45 serotype 19A isolates that were non-susceptible to
erythromycin, 28 (62%) carried the mefE gene. Both the
mefE and ermB genes were carried by all of the CC320
serotype 19A isolates.
Discussion
Prior to the introduction of PCV7, rates of IPD among
Alaska Native children were among the highest reported
in the worldwith vaccine serotypes accounting for 74% of
known serotype IPD (11,12,18). PCV7 was introduced
into the routine childhood vaccine schedule for all
Alaskan children on January 1, 2001. Within three years,
rates of vaccine-type IPD had decreased by 95% and total
IPD rates had declined by 65% among Alaska Native
children B2 years of age (18). While the overall rate of
IPD decreased following the introduction of PCV7, rates
of IPD caused by non-vaccine serotypes increased 140%
compared with the prevaccine period (9). This increase
was in large part due to an increase in IPD caused by
serotype 19A. When compared to the pre-PCV7 era, the
proportion of IPD caused by serotype 19A increased
5-fold from 3.5 to 15.4% across all age groups. Among
children B5 years of age, the group targeted for vac-
cination with PCV7, the proportion increased nearly
7-fold from 5 to 33%. Since the introduction of PCV7,
there have been numerous reports describing increased
rates of IPD with non-vaccine serotypes, particularly
serotype 19A (48, 1925). From these reports, a number
of speculations around possible mechanisms for the
increased incidence of IPD caused by serotype 19A
have emerged and include capsular switching of vaccine
serotypes under selective pressure by PCV7, expansion of
highly resistant strains under antibiotic pressure, intro-
duction of new clones and secular changes in serotype
frequencies to name but a few. It should be noted that
the increased incidence of serotype 19A IPD in various
populations is most likely due to a combination of
multiple factors rather than a single factor.
Examination of the genetic structure of our 19A
isolates revealed that the increase in serotype 19A IPD
was the result of the expansion of pre-existing STs (ST199
and closely related variants and ST172) and the emer-
gence of serotype 19A STs associated with multidrug
resistance, in particular, ST320. However, despite changes
in the 19A population structure in the post-PCV7 era,
CC199 isolates remained the most common genotype.
Prior to the introduction of PCV7, 90% of our 19A
isolates were CC199 isolates. This finding is similar
to what was reported by Beall et al. who found that
 70% of serotype 19A isolates recovered in 1999 from
the Centers for Disease Control and Prevention’s Active
Bacterial Core (ABC) surveillance sites were CC199 (19).
3976
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199 667
172
Fig. 1. Population snapshot of serotype 19A isolates in Alaska
comparing sequence types (ST) found in 19862000 and 2001
2010. Each circle represents a single ST, with the area propor-
tional to the number of isolates of that type. Solid lines between
STs represent single-locus variants. STs in black are STs found
only in the pre-PCV7 (19862000) era. STs in green are STs
found only in the post-PCV7 (20012010) era. STs in pink are
STs found in both the pre-PCV7 and post-PCV7 eras.
Table II. Distribution of serotype 19A genotypes in Alaska by time period, 19862010
Number of isolates (% in time period)
CC or ST
a 19861994 19952000 20012005 20062010 p-value
199 38 (95%) 17 (81%) 33 (63%) 62 (53%) B0.001
172 0 2 (9.5%) 18 (35%) 39 (33%) B0.001
320 0 0 0 15 (13%) 0.001
156 0 0 1 (1.9%) 2 (1.7%)
202 0 1 (4.8%) 0 0
3111 1 (2.5%) 0 0 0
2408 1 (2.5%) 0 0 0
4092 0 1 (4.8%) 0 0
Total 40 21 52 118
aCC/ST clonal complex or sequence type.
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isolates remained predominant among serotype 19A
isolates recovered from children B5 years of age in
20032004, by 2005 CC199 isolates had declined to 59%
of 19A isolates. In Alaska, CC199 serotype 19A isolates
also began declining, dropping to 63% in 20012005 and
53% in 20062010. CC199 has been the predominant
CC in several other studies both prior to and after the
introduction of PCV7 (6,8,23,24,26,27).
In contrast to CC199 serotype 19A isolates, isolates of
ST172 which were first seen in Alaska in 2000, emerged
rapidly after introduction of PCV7 and accounted for
34% of 19A isolates from 2001 to 2010. ST172 isolates
have also been reported among serotype 19A isolates from
the ABC’s surveillance both in the pre- and post-PCV7
eras but accounted for a much lower proportion of
isolates (7,19,28). In contrast, ST172 isolates constituted
69.4% of all tested serotype 19A acute otitis media (AOM)
isolates recovered from Jewish children during an 8-year
study period (19992006) (29). In a more recent study,
ST172 was also found to be predominant among serotype
19A IPD isolates from this same population (30). ST172
isolates within the pneumococcal MLST database have
also been associated with serotypes 6A, 6B, 6C, 15B, 19F,
23B, 23F and 35B. This suggests that capsular switching
may occur more frequently than expected as a number of
different serotypes share the same ST.
The post-PCV7 increase in serotype 19A IPD in
Alaska was also driven by the emergence of ST320
isolates late in the PCV7 era. ST320 is a double-locus
variant of the globally dispersed Taiwan
19F-14 ST236
clone, which is now part of CC320/271 and also contains
ST236 (7). In an ABC’s survey conducted in 20032004,
investigators found that CC320/271 accounted for 13.4%
of the serotype 19A IPD cases in the US (5). The
prevalence of CC320/271 isolates in the US continued
to increase and by 2007 had reached 33%. In Alaska,
CC320/271 (ST320 and ST 1451) isolates were not seen
until 2007 but by 2010, made up 28% of the serotype 19A
isolates. The emergence of CC320/271 among serotype
19A isolates in the post-PCV7 era has not been restricted
to the US and in fact occurred simultaneously in many
different countries (20,22,23,31,32). In contrast, South
Korea reported finding ST320 among both serotype
19F and 19A isolates in the 1990s, well before PCV7
was introduced in that population in 2003 (33). It remains
unclear as to why ST320 serotype 19A isolates would
emerge without vaccine pressure against serotype 19 but
does suggest that vaccination may not be the only factor
responsible for the observed increase in serotype 19A.
Other populations have also seen an increase in the
incidence of serotype 19A in the absence of vaccine
pressure which provides further evidence that a number
of factors, including antibiotic use, may be involved in the
emergence of non-vaccine types (29).
Prior to the introduction of PCV7 in Alaska, PCV7
serotypes accounted for 86% of invasive isolates non-
susceptibletopenicillin, erythromycin, orTMP-SMX(12).
Consequently, after PCV7 introduction the proportion of
isolateswith reduced susceptibility to these antimicrobials
declined (9). Similarly, among ABC surveillance sites,
rates of IPD caused by penicillin-non-susceptible strains
and strains non-susceptible to multiple antibiotics de-
creased between 1999 and 2004 among both children and
adults (35). However, during this same time period, the
proportion of penicillin-non-susceptible serotype 19A
isolates increased significantly (7). In addition, the pro-
portion of serotype 19A isolates that were non-susceptible
to other antibiotics and multiple antibiotics increased and
was seen in the US and elsewhere (7,20,23,29,30). Similar
trends were seen in Alaska where the proportion of sero-
type 19A isolates with reduced susceptibility to penicillin
increased from 52% in the pre-PCV7 era to 71% in the
post-PCV7 era. We also observed a significant increase in
the proportion of serotype 19A isolates that were resistant
to erythromycin, TS and multiple antibiotics.
Table III. Proportion of IPD isolates non-susceptible to antibiotics by time period, 19862000 vs. 20012010, Alaska
Serotype 19A All other serotypes
Number of isolates (%) Number of isolates (%)
19862000 20012010 19862000 20012010
Antibiotic N63 N170 p-value N1760 N897 p-value
Penicillin 32 (52%) 121 (71%) 0.005 148 (8%) 68 (8%) 0.460
Tetracycline 2 (3%) 16 (9%) 0.166 49 (3%) 28 (3%) 0.617
Erythromycin 3 (5%) 45 (27%) B0.001 153 (9%) 68 (8%) 0.328
TS
a 12 (22%) 126 (74%) B0.001 283 (16%) 109 (12%) 0.007
Cefotaxime 3 (5%) 13 (7%) 0.327 59 (3%) 22 (3%) 0.204
Ceftriaxone 3 (5%) 14 (9%) 0.411 39 (2%) 14 (2%) 0.607
3 or more classes 4 (6%) 35 (21%) 0.010 105 (6%) 39 (4%) 0.083
aTStrimethoprim-sulfamethoxazole.
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the serotype 19A isolates that we observed in the post-
PCV7 era was the result of a shift in the genetic structure
of the 19A population. The increase in penicillin non-
susceptibility was the result of an increase in ST172,
which was typically intermediately resistant to penicillin
and CC320 isolates which were fully resistant to penicillin
(MIC]2 mg/ml). In addition to penicillin resistance,
CC320 isolates were resistant to tetracycline, cefotaxime,
ceftriaxone, erythromycin and TMP-SMX. Multidrug
resistance among CC320/271 isolates has been reported
by others and suggests that this high-level antimicrobial
resistance phenotype may have played a role in the
emergence of this clone (6,20,23,28,32). The increase
in erythromycin and TS-non-susceptibility was also
the result of an increase in non-susceptibility among
CC199 isolates. Prior to the introduction of PCV7,
CC199 were typically susceptible to all antibiotics or
non-susceptible to penicillin and/or TS. In the late PCV7-
era, erythromycin-resistant CC199 isolates were recov-
ered. All of these isolates carried the mefE gene which
was, in contrast to the CC320 isolates which carried both
mefE and ermB genes, a phenotype commonly seen
among the Taiwan
19F-14 ST236 clone (33).
In conclusion, the increase in serotype 19A IPD in
Alaska was driven by the expansion of clones existing
prior to PCV7 introduction, particularly ST172 and the
emergence of multidrug-resistant clones that evolved as a
result of capsule switching. Serotype 19A is included in
the recently licensed PCV13 vaccine, and as expected, we
have seen a decline in IPD caused by 19A in Alaska (34).
However, since other serotypes with similar characteris-
tics and disease potential may be the next in line to
expand, surveillance of serotypes, sequences types and
antimicrobial resistance remain important activities to
continue as we introduce higher valency pneumococcal
conjugate vaccines.
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